$2.5m cash versus $5.9m operating burn leaves a thin runway

What changed

Revenue from customers rose to $357.7k from $24.2k, a 1,376% increase that reflects the company's first international sales following the February 2023 Motagon supply agreement for Poland. The headline losses narrowed on every line: PBT loss of $6.0m vs $7.5m (improved 20.4%), NPAT loss of $6.0m vs $8.6m (improved 31.0%), and operating cash outflow of $5.9m vs $6.8m. Capex fell sharply to $73.8k from $400.1k, consistent with a post-build phase. The balance sheet compressed materially: total assets fell 37.6% to $21.0m, total liabilities collapsed 91.1% to $0.8m, inventories dropped 93.5% to $14.3k, and equity eased 16.9% to $20.1m. Cash rose to $2.5m from $1.9m, assisted by capital rather than trading. No dividend was declared.

What matters

• Runway is the dominant issue. Closing cash of $2.5m sits against an FY23 operating outflow of $5.9m and FCF of -$6.0m. Without a capital event, that is well under six months of burn on FY23 run-rate.
• H2 was materially worse than H1 suggested. HY23 posted an NPAT of +$0.7m (flattered by fair value gains on biological assets, per the release's own distinction between "revenue from customers" and "revenue incl. fair value gains"). The implied H2 NPAT is -$6.7m, meaning trading economics deteriorated sharply once the fair value tailwind is stripped out.
• The NPAT improvement overstates operating progress. FY22 carried a $1.15m tax charge (15.4% effective rate) while FY23 tax was immaterial at 0.8%. PBT growth of 20.4% is the cleaner operating read; the 31.0% NPAT improvement is flattered by the tax line normalising.

Expectations

No quantified FY24 guidance, target or forward-work backlog is disclosed in the supplied release. Management described the year as "in line with expectations" and confirmed the first international sales. Seasonality context is limited to HY23, which contributed only 17.6% of full-year revenue — the business is genuinely H2-weighted on the top line, but the H2 P&L was also where the deeper loss was absorbed once non-cash valuation gains unwound. The release supports the claim of a pipeline shifting from build to sell; it does not support any inference about the slope of the FY24 revenue curve or the timeline to cash-flow breakeven.

Quality of result

Low-to-moderate. The narrower PBT loss is real, but the drivers are a mix of reduced capex, lower inventory carry (down $204.5k), and a smaller cost base rather than gross-margin evidence — no gross margin or segment disclosure is provided. The $98.6k trade receivable implies roughly 101 debtor days on FY23 revenue, which is high for a company this early in monetisation and warrants monitoring as volumes scale. Inventory days fell from an extreme ~3,297 to ~15, consistent with a stock write-down or sell-through rather than ongoing operating normalisation. The liabilities line dropping from $9.4m to $0.8m is striking and the supplied extracts do not explain it. H1's reported profit was a fair-value artefact, not a trading result.

Unresolved

• What drove the $8.5m collapse in total liabilities, and does any of it represent deferred obligations being reclassified or settled via equity?
• What is the gross margin on the first international shipments, and is the Motagon contract priced to contribute cash margin at scale?
• What is the funding plan given a $2.5m cash balance against a $5.9m annual operating outflow, and is any capital raise, debt facility or grant income contemplated?
• Why did inventory fall 93.5% — sell-through, write-down, or reclassification — and is any of the reported revenue recognition linked to that unwind?
• What share of the $6.5m "revenue including fair value gains" figure is non-cash biological asset revaluation, and how will that line behave in FY24?

This briefing cannot assess the company's funding intentions, the commercial margin profile of the Motagon agreement, or any post-balance-date capital actions, because none of those disclosures are present in the supplied extracts.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.